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Dementia with Lewy bodies
Glial cytoplasmic inclusions
Lewy bodiesα-Synucleinopathies (ASP) comprise adult-onset, progressive neurodegenerative disorders such as Parkinson's
disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) that are characterized by
α-synuclein (AS) aggregates in neurons or glia. PD and DLB feature neuronal AS-positive inclusions termed
Lewy bodies (LB)whereas glial cytoplasmic inclusions (GCIs, Papp–Lantos bodies) are recognized as the deﬁning
hallmark of MSA. Furthermore, AS-positive cytoplasmic aggregates may also be seen in astroglial cells of PD/DLB
and MSA brains. The glial AS-inclusions appear to trigger reduced trophic support resulting in neuronal loss.
Moreover, microgliosis and astrogliosis can be found throughout the neurodegenerative brain and both are key
players in the initiation and progression of ASP. In this review, we will highlight AS-dependent alterations of
glial function and their impact on neuronal vulnerability thereby providing a detailed summary on the multifac-
eted role of glia in ASP.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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α-Synucleinopathies (ASP) are progressive, adult-onset neuro-
degenerative diseases that include Parkinson's disease (PD), dementia
with Lewy bodies (DLB) and multiple system atrophy (MSA)
(Spillantini and Goedert, 2000; Goedert, 2001; Beyer and Ariza, 2007).ect.com).
. This is an open access article underThe main pathological hallmark of these diseases is the occurrence of
hyperphosphorylated, misfolded and ﬁbrillized α-synuclein (AS)-
positive inclusions throughout the central nervous system (CNS)
(Fujiwara et al., 2002; Uversky, 2008; Vilar et al., 2008). In PD and
DLB, neurons are the main cell type displaying cytoplasmic AS-
positive aggregations which are called Lewy bodies (LB) and Lewy
neurites (LN) (Baba et al., 1998; Beyer and Ariza, 2007), whereas in
MSA, these inclusions predominantly develop in oligodendroglia and
are therefore named glial cytoplasmic inclusions (GCIs, Papp–Lantos
bodies) (Spillantini et al., 1998; Dickson et al., 1999; Hasegawa et al.,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
263D. Brück et al. / Neurobiology of Disease 85 (2016) 262–2742004; Song et al., 2009; Fellner et al., 2011; Fellner and Stefanova, 2013).
Furthermore, PD and DLB show AS depositions in astrocytes and
oligodendrocytes (Wakabayashi et al., 2000; Braak et al., 2007; Song
et al., 2009). Wenning and Jellinger described AS-positive deposits in
astroglial cells in MSA (Wenning and Jellinger, 2005), however they
appear to be less prominent and sometimes absent (Song et al., 2009)
compared to neuronal and oligodendroglial inclusion pathology. AS
aggregation in astroglial cells and its relevance to disease initiation
and progression require further attention in MSA.
The brain protein AS is predominantly located in presynaptic
terminals of neurons in the hippocampus, striatum, thalamus, cerebel-
lum and neocortex (Iwai et al., 1995; Norris et al., 2004). AS belongs
to a family of three distinct genes, including SNCA, SNCB and SNCG (α-,
β- and γ-synuclein) and is composed of 140 amino-acids (Dev et al.,
2003; Eriksen et al., 2003). Although the precise function of the protein
is not solved yet, the importance of AS in folding and refolding of
synaptic proteins has been proven (Chandra et al., 2005). Moreover,
AS directly interacts with phospholipid vesicle membranes suggesting
an important regulatory role in both inhibitory and facilitatory
transmitter releases (Auluck et al., 2010) (Abeliovich et al., 2000;
Cabin et al., 2002; Gitler and Shorter, 2007).
The development of the AS-positive GCI, LB and LN has not been
completely elucidated yet. However, different studies demonstrated
that AS overexpression impairs macroautophagy suggesting that
reduced AS clearance is involved in the generation of AS inclusions in
DLB and PD (Winslow et al., 2010; Xilouri and Stefanis, 2011). Further-
more, alterations in the autophagosomal proteins inMSA brains and the
participation of macroautophagy in the MSA pathogenesis have been
suggested (Tanji et al., 2011; Schwarz et al., 2012). Post-translational
modiﬁcations of AS, such as ubiquitination, nitration and phosphoryla-
tion may promote pathological inclusion formation and enhance
disease progression (Giasson et al., 2000; Tofaris et al., 2003; Xilouri
and Stefanis, 2011). Moreover, Ozawa et al. showed a connection
between neuronal cell loss, aggregation of AS and disease severity
in MSA (Ozawa et al., 2004). Prion-like cell-to-cell propagation of AS
has been suggested a crucial contributor to neurodegeneration and
therefore to the progression of ASP (Desplats et al., 2009; Lee et al.,
2010; Hansen et al., 2011; Reyes et al., 2014).
Glial cells are important in supporting neuronal survival, synaptic
functions and local immunity (Webster and Astrom, 2009; Hauser
and Cookson, 2011). However, glial cells might be crucial for the
initiation and progression of different neurodegenerative diseases, in-
cluding ASP (Gerhard et al., 2003, 2006; Fellner et al., 2011; Halliday
and Stevens, 2011). Due to various stimuli, e.g. infection or injury,
astroglial and microglial cells get activated (Nimmerjahn et al., 2005;
Wilhelmsson et al., 2006). Neurons may beneﬁt from activated microg-
lia and astroglia due to the release of trophic factors or the clearance of
damaged cells by microglia (Liberto et al., 2004; van Rossum and
Hanisch, 2004; Nimmerjahn et al., 2005; Wilhelmsson et al., 2006).
Especially in neurodegenerative diseases microglia and astroglia can
get over activated resulting in reactive microgliosis and astrogliosis. It
was described that astroglial cells can activate microglial cells (Gu
et al., 2010; Halliday and Stevens, 2011; Schmidt et al., 2011), or vice
versa microglial activation can induce astrogliosis (Balasingam et al.,
1996; Hanisch, 2002; Rohl et al., 2007). Reactive gliosis might induce
neurotoxicity, perturbation of the neuronal network, and maladaptive
plasticity and further lead to tissue damage (Papa et al., 2014).
Moreover, it was demonstrated that neuronal cells have the ability to
release excessive AS leading to the activation of an inﬂammatory re-
sponse in microglia (Lee et al., 2010; Kim et al., 2013). Furthermore,
the before mentioned prion-like spreading of pathological AS (Luk
et al., 2009; Hansen et al., 2011; Masuda-Suzukake et al., 2013; Watts
et al., 2013) could be a possible mechanism of AS aggregation in ASP
and further cause activation of microglia and astroglia. Aggregated AS
was shown to induce reactive microgliosis resulting in dopaminergic
cell death (Zhang et al., 2005). Glial overactivation results in the releaseof (pro)-inﬂammatory cytokines, nitric oxide (NO) and reactive oxygen
species (ROS) (Neumann et al., 2002; Deshpande et al., 2005; Mizuno
et al., 2005; Zhang et al., 2005; Qian and Flood, 2008; Dean et al.,
2010; Lee et al., 2010; Qian et al., 2010).
Besides, oligodendroglial cells that are exposed to oxidative stress
and cytokines present with cellular dysfunction, demyelination and
cell death, as well as reduced trophic support which consequently
affects neuronal survival (Thorburne and Juurlink, 1996; Jurewicz
et al., 2005).
This review summarizes the main features of ASP and the involve-
ment of glial cells regarding the initiation and progression of these
neurodegenerative diseases. We will discuss the main changes of glial
cells during disease initiation and progression.Glia in PD and DLB
PD and DLB are common neurodegenerative diseases in the popula-
tion over the age of 65. About 3% of the general population develops PD
after the age of 65, whereas about 20% of all diagnosed dementia
patients have DLB (McKeith, 2004; Dorsey et al., 2007). In both disor-
ders movement and cognition, as well asmood and autonomic function
are severely affected. Diagnosis to distinguish PD and DLB is very difﬁ-
cult, because of the overlap of symptoms and signs (Henchcliffe et al.,
2011). In search for new biomarkers different factors were examined
in the cerebrospinal ﬂuid (CSF) of PD and DLB patients in comparison
with Alzheimer disease (AD) patients and controls. Nagatsu and
colleagues described elevated levels of pro-inﬂammatory cytokines
such as Interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6, as
well as decreased levels of neurotrophins such as brain-derived neuro-
trophic factor (BDNF) in the ventricular or lumbar CSF of PD patients
(Nagatsu and Sawada, 2005). Moreover, elevated levels of the astroglial
protein glial ﬁbrillary acidic protein (GFAP), as well as the neuroﬁla-
ment light protein (NFL), which is used as amarker of neuronal damage,
and AS were found in the CSF of PD patients (Constantinescu et al.,
2010; Gao et al., 2014). Different studies could show that CSF AS levels
are lower in PD and DLB compared to AD patients and controls
(Mollenhauer et al., 2008; Wennstrom et al., 2013). Additionally,
Wennstrom and colleagues described a decrease of neurosin, an AS
degrading protease, in the CSF of patients with PD and DLB
(Wennstrom et al., 2013). Furthermore, it was suggested that an altered
ratio of phosphorylated AS CSF levels might serve as a biomarker to dis-
tinguish PD from controls (Foulds et al., 2011).
Both diseases feature LB consisting of aggregated AS as a hallmark
lesion of degenerating neurons. PD patients show enhanced neuronal
loss in the substantia nigra (SN) compared to DLB patients (Tsuboi
and Dickson, 2005). Immunohistochemical studies showed a signiﬁ-
cantly higher amount of amyloid plaques in the putamen and caudate
nucleus and more severe tau pathology in DLB compared to PD brains.
Additionally, Jellinger and Attems suggested an elevated level of AS-
lesions in DLB compared to PD (Jellinger and Attems, 2006). The accu-
mulation of AS is increased with the occurrence of point mutations or
duplications as well as triplications of the SNCA gene (Polymeropoulos
et al., 1997; Singleton et al., 2003; Zarranz et al., 2004; Nishioka et al.,
2006). Recent studies conﬁrmed the association between PD and both
SNCA single nucleotide polymorphisms (SNPs) and the H1 haplotype
of microtubule-associated protein tau (MAPT) (Edwards et al., 2010;
Elbaz et al., 2011; Trotta et al., 2012). Other genetic risk factors in the
development of PD include leucine-rich repeat kinase 2 (LRRK2), the
human leukocyte antigen (HLA) region and DJ-1 (Bonifati et al., 2003;
Zimprich et al., 2004; Simon-Sanchez et al., 2009; Hamza et al., 2010).
Genetic observations show also overlaps between PD and DLB.
Mutations in the genes encoding AS (El-Agnaf et al., 1998; Ibanez
et al., 2004), LRRK (Zimprich et al., 2004) and glucocerebrosidase
(Goker-Alpan et al., 2006) were found in some DLB patients. How-
ever, also sporadic PD and DLB cases occur suggesting that genetic
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initiation of the disease.
Due to PD progression and the development of LB and LN,
dopaminergic terminals in the striatum and dopaminergic neurons in
SN get affected and ﬁnally degenerate (Fearnley and Lees, 1991;
Jellinger, 2003; Savitt et al., 2006). An attempt to classify the stages of
PD was undertaken in 2003 by Braak and colleagues: (1) The stages
1–2 affect the lower raphe nuclei, lower brainstem nuclei, including
the dorsal motor nucleus of the vagus, the locus coeruleus as well as
the olfactory system. (2) Thereafter, LB pathology affects the SN pars
compacta (SNpc), intralaminar thalamic nuclei, hippocampal CA2 and
amygdala (stages 3–4). (3) Finally, in stages 5–6 of PD LB pathology
expands to the neocortex (Braak et al., 2002, 2003b). Yet, the suggested
Braak stages were challenged for different reasons, one being the lack of
a deﬁnite correlation between clinical course and neuronal loss (Calne
et al., 1992; Parkkinen et al., 2005; Burke et al., 2008; Jellinger, 2009).
Given that neuronal loss is not only dependent on the occurrence of
AS aggregates, different other factors must have a major impact on
disease progression in PD and DLB. Additionally to the AS positive ag-
gregations in neurons and glia, it is suggested that reactive astrogliosis
and microgliosis and therefore chronic inﬂammation play a crucial
role in the initiation and progression of PD and DLB (Fellner et al.,
2011; Halliday and Stevens, 2011). However, as microglia and astroglia
might display beneﬁcial and detrimental effects on neuronal cells, the
complete involvement of glial activation in PD and DLB is contradictory
and has not been elucidated yet (Knott et al., 2002; Hashioka et al.,
2009).
AS-positive inclusions in oligodendroglial cells were also conﬁrmed
in PD brains (Wakabayashi et al., 2000). However, oligodendroglial in-
volvement in neuronal ASP seems not so profound for disease initiation,
but in late disease progression nonmyelinating oligodendroglial cells
may play a more crucial role (Halliday and Stevens, 2011).
Microglia
[(11)C]-PK11195 Positron Emission Tomography (PET) imaging
revealed profoundmicroglial activation especially in pons, basal ganglia,
frontal and temporal cortical regions of PD patients (Gerhard et al.,
2006). Iannaccone et al. described microglial activation in SN and
putamen in PD as revealed by PET (Iannaccone et al., 2013). Moreover,
early-stage drug-naïve PD patients displayed enhanced microglial
activation only in the midbrain which correlated with the loss of
dopaminergic terminals in the striatum using [(11)C]-PK11195 PET
and [(11)C]CFT binding the dopamine transporter (Ouchi et al., 2005).
In a follow-up study, microgliosis also affected extra-striatal regions of
the brain in these PD patients (Ouchi et al., 2009). In post-mortem PD
brains, microglial activation has been identiﬁed in different brain
regions, including SN, putamen, hippocampus, transentorhinal, cingu-
late and temporal cortex, as well as the limbic system (Imamura et al.,
2003). However, profound activation of microglia in the SN, but no in-
ﬂammatory changes such as microgliosis was reported in the putamen
(Mirza et al., 2000). The inconsistent reports regarding microglial acti-
vation in different regions of PD brains might reﬂect the various stages
of the disease and the individual differences of the disease pattern. In
DLB patients, microglial activation in the SN and putamen was found.
Further, comparisons of PD with DLB patients using the [(11)C]-
PK11195 PET revealed additional microglial activation in several
associative cortices in early DLB patients (Iannaccone et al., 2013).
Moreover, reactive microglial cells were found to be more frequent
around AS-positive LB in PD and also DLB (Mackenzie, 2000; Gerhard
et al., 2003), and they were described in close proximity of dying
neurons (Imamura et al., 2003).
In a recent study, post-mortem analyses of PD brains revealed
region-speciﬁc variations of different microglial phenotypes in the SN
and the hippocampus (Doorn et al., 2014). Furthermore, an enhanced
expression of Toll-like receptor 2 (TLR2) on microglia in SN andhippocampus of incidental Lewy Body disease cases, which is thought
to be a prodromal state of PD, and PD patients was described indicating
a role for TLR2 and also microglia in the early stages of PD pathology
(Doorn et al., 2014).
The hypothesis that microglial cells get activated by extracellular
AS or astroglia even before neuronal loss occurs in SNpc has been
proposed previously (Su et al., 2009; Halliday and Stevens, 2011).
These data and theobservations in PDpatients support the presumption
that microglial activation is involved in the initiation and progression of
PD and DLB including the secretion of pro-inﬂammatory cytokines and
ROS.
Especially in many cell culture studies a correlation between AS and
microglial activation was described. The treatment of murine wild type
(wt) microglia with aggregated AS in vitro led to the activation of
antigen processing and presentation of antigen, inducing e.g. cytokine
release (Harms et al., 2013). The PD-associated mutant forms of AS
(A30P, E46K and A53T) extracellular applied, induced microglial
activation in vitro and thus the release of pro-inﬂammatory cytokines
including IL-6, IL-1β and TNF-α and the anti-inﬂammatory cytokine
IL-10 as well as chemokines such as RANTES, monocyte chemotactic
protein 1 (MCP-1), (C-X-C motif) ligand 10 (CXCL-10) and the macro-
phage inﬂammatory protein 1α (MIP-1α) respectively (Roodveldt
et al., 2010). Moreover, it was also shown that AS treatment of human
primary microglial cells causes a dose-dependent release of pro-
inﬂammatory molecules (Klegeris et al., 2008; Su et al., 2008). Experi-
ments with the microglial cell line BV2 revealed that neuron-derived
wt and mutant AS increased the pro-inﬂammatory response, and
primarily mutant AS induced an enhanced release of NO and
inﬂammatory cytokines, such as IL-6 and TNF-α (Alvarez-Erviti et al.,
2011; Rojanathammanee et al., 2011). Furthermore, it was demonstrat-
ed that especially recombinant C-terminally truncated AS induced an
enhanced release of pro-inﬂammatory cytokines (e.g. IL-6, TNF-α) or
chemokines (e.g. CXCL-1) and production of ROS (Fellner et al.,
2013a). In another study it was also found that extracellular aggregated
AS induced NADPH oxidase activation and ROS production in rat prima-
ry mesencephalic microglia which led to dopaminergic neuronal loss
(Zhang et al., 2005). In addition, nitrated and aggregated AS increased
oxidative stress, inﬂammation and neuronal cell death in mesencephal-
ic neuron microglia co-cultures (Zhang et al., 2005; Reynolds et al.,
2008). These studies highlight the impact of AS on microglial cells
and suggest the importance of microglial overactivation on neuronal
survival and therefore, in the progression of PD and DLB.
Another important feature of microglial cells is the clearance of
debris, including dead cells and AS (del Rio-Hortega, 1932; Zhang
et al., 2005; Park et al., 2008), thereby supporting neuronal survival.
Different studies could show thatmicroglial cells are capable of internal-
izing and degrading different forms of extracellular and cell-derived AS
in vitro (Lee et al., 2008; Park et al., 2008; Stefanova et al., 2011; Fellner
et al., 2013a). Recently, it was described that Toll-like receptors (TLRs)
might play an important role in the recognition, internalization and
activation of microglial cells. Particularly, the pattern-recognition
receptors TLR2 and TLR4 were found to play a crucial role regarding
AS phagocytosis and AS-dependent activation (Stefanova et al., 2011;
Fellner et al., 2013a; Kim et al., 2013). Kim and colleagues suggested
TLR2 as a fundamental link between recognition of neuron-released
oligomeric AS, microglial activation and inﬂammatory responses (Kim
et al., 2013). In vivo and in vitro studies showed that TLR4 ablation led
to a disturbed clearance of overexpressed or recombinant AS by
mouse microglia linked to aggravated nigral neurodegeneration
(Stefanova et al., 2011; Fellner et al., 2013a). On the other handTLR4de-
ﬁciency in microglia induced a decreased release of pro-inﬂammatory
cytokines and ROS in response to AS exposure suggesting an involve-
ment of TLR4 in inﬂammation and oxidative stress in ASP (Fellner
et al., 2013a).
Studies performed in different animal models overexpressing AS
highlight the link between AS or modiﬁed forms of AS and microglial
Fig. 1. Microglial involvement in α-synucleinopathies (ASP). Microglial cells can get
activated by pathological α-synuclein (AS) (Su et al., 2009; Halliday and Stevens, 2011;
Fellner et al., 2013a). Different sources of these pathological AS species were proposed
including release by neurons to the extracellular space or cell-to-cell propagation (Braak
et al., 2007; Lee et al., 2010). Activation of microglial cells induces an oxidative stress
response including the release of reactive oxygen species (ROS) and nitric oxide (NO) as
well as the production of NADPH oxidase. Furthermore, pro-inﬂammatory cytokines,
such as Interleukin-1β (IL-1β), IL-6, and tumor necrosis factor α (TNF-α), and the anti-
inﬂammatory cytokine IL-10 as well as pro-inﬂammatory chemokines including (C-X-C
motif) ligand 1 (CXCL-1), CXCL-10, Rantes, monocyte chemotactic protein 1 (MCP-1),
and macrophage inﬂammatory protein 1α (MIP-1α) are released by activated microglial
cells (Zhang et al., 2005; Su et al., 2008; Roodveldt et al., 2010; Alvarez-Erviti et al.,
2011; Rojanathammanee et al., 2011; Fellner et al., 2013a). An involvement of Toll-like
receptor 4 (TLR4), TLR2 and myeloperoxidase (MPO, key enzyme related to oxidative
stress during inﬂammation) in inﬂammation and oxidative stress has been suggested
(Stefanova et al., 2012a; Fellner et al., 2013a; Kim et al., 2013). Inﬂammation and oxidative
stress mediated through microglial cells can further lead to neuronal dysfunction and cell
death (Zhang et al., 2005; Reynolds et al., 2008). Thereby, dying neurons might release
accumulated AS that stays in the extracellular space and again leads to the activation of
microglial cells. This feedback loop might increase microglial activation leading to
microgliosis. However, microglial cells are also able to phagocytose different forms of
extracellular AS via TLR4 (Stefanova et al., 2011; Fellner et al., 2013a). This clearance
mechanism might be even beneﬁcial for neuronal survival. The different features
displayed by microglial cells make it hard to categorize the role of microglial cells in
ASP. Yet, the detrimental and beneﬁcial functions of microglial cells suggest an
involvement of microglial activation in the initiation and progression of ASP (Halliday
and Stevens, 2011). However, further studies have to be conducted to understand the
complete participation of microglial activation in ASP.
265D. Brück et al. / Neurobiology of Disease 85 (2016) 262–274activation. The following studies were able to demonstrate the impor-
tance ofmicroglial activation in PD andDLB and the impact ofmicroglial
activation on dopaminergic neuronal survival which indicates a leading
role for microglial cells in disease initiation and progression. In a mouse
model overexpressing wt AS under the rat tyrosine hydroxylase
promoter premature microglial activation was detected (Su et al.,
2008). Moreover, enhanced microglial activation was described in
mice overexpressing mutant human AS (A53T and A30P homozygous
double-mutants) under a neuronal promoter (Su et al., 2009). Interest-
ingly, the intramuscular injections of ﬁbrillized AS in mice expressing
the mutant human A53T AS led to a widespread CNS AS-inclusion pa-
thology with elevated levels of microgliosis in brain areas presenting
AS pathology compared to control animals (Sacino et al., 2014). A
correlation between the level of AS expression and cell numbers of
microglia was found in a rat PDmodel with rAAV-based overexpression
of AS in midbrain (Sanchez-Guajardo et al., 2010). Furthermore, in this
rat model delayed but long lasting microglial activation upon dopami-
nergic degeneration was described. An early and transient activation
of microglial cells was induced although no dopaminergic cell death
occurred. In the rat model with rAAV-based overexpression of AS
the progression of the neurodegeneration was associated with four
different types of microglial activation (Sanchez-Guajardo et al.,
2010). Moreover, it has been suggested that modiﬁed forms of AS,
particularly nitrated species, may be released as a consequence of
dopaminergic neurodegeneration and that these trigger subsequent
immune responses (Theodore et al., 2008). Evidence has been provided
that a PD mouse model with rAAV-based human AS overexpression
triggered microglial activation and further stimulated the adaptive
immune system (Theodore et al., 2008). Microglial cells lacking the Fc
gamma receptor, which participates in the regulation of the immune
response by binding antibodies, can be activated by AS, further leading
to stress and therefore to NF-κB/p65 expression, the release of pro-
inﬂammatory cytokines as well as neurodegeneration respectively.
These results suggest an involvement of the humoral adaptive immune
system in AS-mediated microglial activation and neuronal cell death
(Cao et al., 2010). It was described that glucocorticoid receptors are
decreased in the SN of PD patients and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-intoxicated mice. Therefore, in a recent
study the knock-out of glucocorticoid receptors, which are involved in
the immune response and inﬂammation by binding cortisol and gluco-
corticoids that can be released during stress, on microglia in an MPTP
mouse model has been characterized and revealed increased dopami-
nergic neurodegeneration in a model for parkinsonism (Ros-Bernal
et al., 2011). In a different approach it was found that rats with induced
inﬂammation in the midbrain and exposed to stress showed an in-
creased microglial activation resulting in a higher rate of dopaminergic
neuronal cell death, suggesting that stress might increase the progres-
sion of PD (de Pablos et al., 2014).
In conclusion, microglial activation is a very important mechanism
in PD and DLB and seems to occur in correlation with the AS pathology
in the CNS as seen in experimental models. However, the exact role of
microglial cells has not been elucidated completely in these neurode-
generative diseases. On the one hand, microglial cells contribute to the
clearance of debris, dead cells and AS thereby supporting neuronal
survival. But on the other hand, microglial cells can get over activated
in the course of the disease and might contribute to disease initiation
and progression by enhancing neurodegeneration through elevated
oxidative stress and inﬂammatory processes (Fig. 1).
Astroglia
Astroglial cells may play an important role in PD and DLB, as they
display AS-positive accumulations in the cytoplasm and an activated
phenotype in these diseases. In DLB brains, processes of astroglia that
were TNF-α and inducible nitric oxide synthase (iNOS)-positive were
characterized around AS-positive irregular LB (Katsuse et al., 2003).Different reports exist on astroglial activation in PD. Astroglial activation
in PD post-mortem brains has been described as not existing, mild or
marked. Different studies proposed that no reactive astroglial cells
occurred in the SN, putamen and pons of PD brains (Mirza et al., 2000;
Song et al., 2009). Hirsch and colleagues conducted PD post-mortem ex-
aminations and revealed massive astrogliosis and loss of dopaminergic
neurons in the SN (Hirsch et al., 2005), whereas Vila et al. suggested a
mild extent of reactive astroglia (Vila et al., 2001). At this time point
regarding the current literature, it is not possible to conclude if astroglial
activation occurs in PD brains, suggesting a large variability in human
PD patients. Moreover, many different factors could be responsible for
the activation of astroglial cells in PD and also the different methods
used for the analyses of astroglial activation in post-mortem brains
could lead to these differing results. More neuropathological studies
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perimental data favor astroglial activation triggered by AS, as discussed
further in the text.
Furthermore, in PD post-mortem brains, it was described that
interferon-γ (IFN-γ) activationmight lead to a neurotoxic reaction indi-
cated by an increased amount of IFN-γ receptor on astroglia (Hashioka
et al., 2009, 2010). In addition, an astroglial-dependent upregulation of
the expression of myeloperoxidase, a key enzyme related to oxidative
stress during inﬂammation, in the ventral midbrain of PD patients was
found (Choi et al., 2005). However, also the release of beneﬁcial factors
by human astroglial cells was reported, including e.g. the brain-derived
neurotrophic factors in SN of PD brains (Knott et al., 2002). Moreover,
enhanced levels of glutathione peroxidase (GPx), a crucial protective
enzyme against oxidative damage, in association with astroglial prolif-
eration were reported in the SN of PD brains (Damier et al., 1993).
Thus, the enhanced GPx activity was associated with elevated levels of
the astroglial marker GFAP (Mythri et al., 2011) indicating that
astroglial cells might be crucial for the protection of neurons against ox-
idative stress.
It is well known that neuronal depositions of AS serve as a patholog-
ical hallmark of PD and DLB, however AS-positive protein aggregates
were also described in human astroglial cells (Wakabayashi et al.,
2000). Moreover, it was proposed that PD initiation starts inter alia
with early nonﬁbrillized AS deposition in the cytoplasm of astroglia
leading to the activation of microglial cells and neuronal cell death
respectively (Halliday and Stevens, 2011) as supported in two indepen-
dent in vivo studies described further in the following section (Gu et al.,
2010; Schmidt et al., 2011). Furthermore, it is suggested that altered AS,
released by axon terminals, is taken up by astroglial cells surrounding
the synapses (Braak et al., 2007), supporting the hypothesis of
neuron-to-astroglia propagation of AS characterized in a different
study (Lee et al., 2010). Moreover, Song and colleagues discovered
that only human protoplasmic astroglia showed an elevated cytoplas-
mic AS accumulation in PD, whereas no obvious changes were seen in
ﬁbrous astroglia (Song et al., 2009). A more detailed characterization
would be beneﬁcial to clarify if and why only certain astroglial sub-
groups are accumulating AS and the impact of astroglial AS aggregation
on neuron and other glial cell survival as well as disease progression.
Various experimental studies were able to shed light on different
aspects of incorporation of AS by astroglial cells resulting in the release
of pro-inﬂammatory but also anti-inﬂammatory molecules. Lee and
colleagues conﬁrmed that direct transfer of overexpressed AS from
human derived SH-SY5Y neurons to rat astroglial cells takes place and
furthermore, induces an inﬂammatory response in ASP suggesting a
prion-like spread of the disease (Lee et al., 2010). Furthermore, uptake
of neuronal-derived or recombinant AS in a time-dependent manner
by human astroglial cells leading to impaired mitochondrial function
was reported recently (Lee et al., 2010; Braidy et al., 2013). In another
cell culture study, primarymurine astroglial cells incorporated different
forms of recombinant AS (soluble, ﬁbrillized and truncated) by a TLR4-
independent mechanism suggesting an endocytotic pathway of uptake
(Fellner et al., 2013a) as also proposed by Lee et al. (2010). The addition
of extracellular AS to human astroglial cell cultures led to an accelerated
production and release of pro-inﬂammatory cytokines including IL-6
and intercellular adhesionmolecule 1 (ICAM-1), and inmurine astroglia
it induced the release of IL-6, TNF-α, the chemokine CXCL-1 and ROS
(Klegeris et al., 2006; Fellner et al., 2013a). However, TLR4 ablation led
to a decreased production of pro-inﬂammatory cytokines and ROS
upon treatment with recombinant AS (Fellner et al., 2013a) indicating
an important role for TLR4 in astroglial activation. Moreover, neuro-
protective molecules might be released by astroglial cells when activat-
ed. It was found that hydrogen sulﬁde, a potential anti-inﬂammatory
and neuroprotective agent, was downregulated upon astroglial
activation indicating a possible role in neurodegeneration (Lee et al.,
2009). In addition, the release of the glial cell line-derived neurotrophic
factor (GDNF) by astroglia activated by selective dopaminergic neuronaldamage was reported (Saavedra et al., 2006) suggesting a neuroprotec-
tive function for astroglial cells. Supporting the neuroprotective
function of astroglia, the release of the antioxidant glutathione by
astroglia upon dopaminergic injurywas described (Sandhu et al., 2009).
Different in vivo studies could show that astroglial activation or
astrogliosis in combination with the secretion of pro-inﬂammatory
cytokines contribute to the progression of PD and eventually also DLB
conﬁrming human post-mortem data. An increased expression of INF-
γ receptor on astroglia, as well as TNF-α immunoreactivity related to
astroglia were characterized in MPTP-treated monkeys (Parkinsonian
macaques), suggesting that astroglial overactivation could play a crucial
role in the progression of PD (Barcia et al., 2011). Furthermore,
microgliosis and fast progressing paralysis triggered by widespread
astrogliosis was themain ﬁnding in an inducible mousemodel express-
ing the mutant A53T AS variant in astroglial cells. In addition, the over-
expression of themutant AS in astroglial cells inmice altered thenormal
function of astrocytes leading to a reduced integrity of the blood–
brain barrier, a decreased homeostasis of extracellular glutamate and
inducing a signiﬁcant loss of dopaminergic neurons in the midbrain
and motor neurons in the spinal cord (Gu et al., 2010). In a different
study, the PD mouse model overexpressing mutant AS presented with
morphological and functional alterations in astroglial mitochondria
and a deranged secretion of factors fundamental for neuronal differen-
tiation (Schmidt et al., 2011). These ﬁndings suggest that the accumula-
tion of AS in astroglial cells might be of importance in the initiation of
PD as also suggested by Halliday and Stevens in 2011 (Halliday and
Stevens, 2011). In a recent study, it was shown that PD mutant mice
overexpressing human AS and the transglutaminase 2 (TG2) showed a
promoted aggregation of AS and also an elevated astroglial activation
compared to mice only overexpressing AS suggesting a signiﬁcant
contribution of TG2 to the accumulation of AS and pathogenesis of PD
and other ASP and therefore a novel target regarding therapeutic ap-
proaches (Grosso et al., 2014).
In summary, the accumulation of AS in astroglial cells may function
as a crucial factor in the initiation of PD (Halliday and Stevens, 2011). In
addition, progression of disease might be driven by astroglial release of
pro-inﬂammatory cytokines/chemokines, ROS and recruitingmicroglial
cells (Fig. 2). However, astroglial cells might also support neuronal
survival through the secretion and production of neurotrophic and anti-
oxidant factors induced by neuronal cell death. As there are not enough
data supporting AS-dependent astroglial neuroprotection, more
research will be necessary to identify the role of astroglial cells in the
initiation and progression of PD and DLB.
Oligodendroglia
It is suggested that oligodendroglial cells do not play a leading role in
PD and DLB, however they might be involved in the late disease
progression of these neuronal ASP (Halliday and Stevens, 2011). Oligo-
dendroglial AS-positive inclusions are present in the brains of clinical
overt PD cases, yet with a rather low distribution that correlates with
the degree of neurodegeneration in SN (Arai et al., 1999; Wakabayashi
et al., 2000). However, no inclusions in oligodendroglial cells of preclin-
ical Lewy body disease have been described (Wakabayashi et al.,
2000). In addition, the occurrence of oligodendroglial cells showing
complement-activation has been shown in some brain regions of PD
and DLB cases (Yamada et al., 1992). Poor and protracted myelination
due to neurodegeneration in PD and DLB led to a higher susceptibility
of oligodendroglial cells (Braak and Del Tredici, 2004). Moreover, a co-
localization of AS-affected neurons with an enhanced number of
nonmyelinating oligodendroglial cells has been described (Braak et al.,
2003a; Braak and Del Tredici, 2009). These ﬁndings highlight that
oligodendroglial cells might not play a crucial role in the initiation and
progression of disease pathology in PD and DLB. However, the involve-
ment of oligodendroglial cells in the beginning of neuronal ASP has not
been fully elucidated by now.
Fig. 2. Astroglial involvement in α-synucleinopathies (ASP). Astroglial cells are activated
by different forms of α-synuclein (AS). Different sources of these pathological AS species
were proposed including release by neurons or cell-to-cell propagation (Braak et al.,
2007; Lee et al., 2010). Thereby AS-induced release of intercellular adhesion molecule 1
(ICAM-1), reactive oxygen species (ROS) and pro-inﬂammatory cytokines [e.g. Interleukin-
6 (IL-6) and tumor necrosis factorα (TNF-α)] wasmeasured (Klegeris et al., 2006; Fellner
et al., 2013a). An involvement of Toll-like receptor 4 (TLR4), myeloperoxidase (MPO, key
enzyme related to oxidative stress during inﬂammation) and hydrogen sulﬁde in
inﬂammation and oxidative stress has been suggested (Choi et al., 2005; Lee et al.,
2009; Fellner et al., 2013a). Furthermore, various studies found that astroglial cells can
internalize extracellular or neuron-derived AS via endocytosis (Lee et al., 2010; Braidy
et al., 2013; Fellner et al., 2013a). As a consequence, AS-dependent inﬂammation and
oxidative stress and the uptake and accumulation of ASmight inducemicroglial activation
as well as neuronal dysfunction and neurodegeneration (Lee et al., 2009; Gu et al., 2010).
Astroglial cells are highly involved in inﬂammation and neuronal cell death. Some
neuroprotective features were described for astroglial cells, yet not in an AS-dependent
context (Saavedra et al., 2006; Sandhu et al., 2009). Further studies have to be completed
to elucidate the role of AS-endocytosis and to understand the complete picture of
astroglial involvement in ASP.
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MSA is a progressive neurodegenerative disorder characterized by
cerebellar ataxia, parkinsonism and autonomic dysfunction in any
combination. MSA is categorized as a rare disease with a prevalence of
about 4.4 per 100,000 cases (Schrag et al., 1999) and an onset of disease
at about 52–57 years of age (Kollensperger et al., 2008; O'Sullivan et al.,
2008). Furthermore, MSA is classiﬁed into 2 different clinical subtypes,
being on the one hand MSA-P presenting levodopa-unresponsive
Parkinsonismdue to SND and on the other handMSA-Cmainly showing
cerebellar ataxia reﬂecting olivopontocerebellar atrophy (Gilman et al.,
1999; Wenning et al., 2004, 2013; Stefanova et al., 2009; Wenning and
Stefanova, 2009; Jecmenica-Lukic et al., 2012). Both subtypes are char-
acterized by progressive autonomic failure combined with degenera-
tion in intermediolateral cell columns, Onuf's nucleus in the spinal
cord and autonomic brainstem centers (Wenning et al., 1997; Ozawa
et al., 2004). Furthermore, MSA is hallmarked by so called Papp–Lantos
bodies or GCIs which are located in the cytoplasm of oligodendroglia.
The inclusions are histopathologically characterized by aggregated
and phosphorylated (Ser129) AS similar to LB and reside in the
movement, balance, and autonomic control centers of the brain
(Jellinger and Lantos, 2010). Due to these AS-positive GCIs and their
broad distribution throughout the CNS, MSA is conceptualized as a
primary oligodendrogliopathy (Wenning et al., 2008).
Polymorphisms within the SNCA gene might induce the develop-
ment of MSA (Al-Chalabi et al., 2009; Scholz et al., 2009). However,
in different studies and in a genome-wide association study thepolymorphisms in the SNCA gene in MSA could not be conﬁrmed
(Ozawa et al., 1999; Yun et al., 2010; Ahmed et al., 2012). Impairment
of COQ2 and therefore inducing a functional impairment of the mito-
chondrial respiratory chain and enhanced vulnerability to oxidative
stress were described in Japanese patients recently (Multiple-System
Atrophy Research, C, 2013), yet no such correlation between loss-of-
function of COQ2 variants and increased risk of MSA in Europeans and
Koreans was found (Jeon et al., 2014; Schottlaender et al., 2014;
Sharma et al., 2014). These genetic data suggest that possible environ-
mental risk factors and genetic predisposition might lead to MSA
(Kuzdas-Wood et al., 2014). Furthermore, MSA is also characterized
by microgliosis and astrogliosis in different affected regions of the
brain (Gerhard et al., 2003; Ishizawa et al., 2004). However, the exact
function ofmicroglial and astroglial cells inMSA has not been complete-
ly elucidated to this date.
Similar to PD and DLB, biomarkers to distinguish MSA from other
ASP and AD would increase the probability of an early diagnosis. A CSF
study in MSA described a signiﬁcant decrease of SNCA levels compared
to controls and AD cases. However, no signiﬁcant differences were
determined between MSA and PD or DLB (Tateno et al., 2012). Further-
more, it was suggested that an altered ratio of phosphorylated AS CSF
levels might serve as a biomarker to distinguish PD from MSA (Wang
et al., 2012). Yet, others did not ﬁnd signiﬁcant differences between
CSF samples of MSA patients and PD or DLB patients or controls
(Mollenhauer et al., 2011; Shi et al., 2011; Aerts et al., 2012).
Microglia
Similar to PD and DLB microglial activation has been described
repeatedly in MSA. Using [11C](R)-PK11195 PET imaging microglial ac-
tivation was detected in the dorsolateral prefrontal cortex, putamen,
pallidum, pons and SN inMSA patients (Gerhard et al., 2003). Addition-
ally, an upregulation of activated microglial cells was found to be
associated with GCI pathology in motor-related structures (Ishizawa
et al., 2004).
Various in vitro data on AS-dependent microglial activation are of
equal relevance for PD, DLB and MSA. The appropriate studies are
already discussed in the ﬁrst part of the review “glia in PD and DLB”
(microglia) and AS-dependent microglial activation might contribute
similarly to the initiation and progression in MSA compared to PD and
DLB.
Age-dependent, region-speciﬁc chronic microglial activation was
also demonstrated in the transgenic MSAmouse model overexpressing
AS under an oligodendroglial promoter (Stefanova et al., 2007). It was
shown that early microglial activation in SNpc of MSA mice was associ-
ated with an elevated expression of iNOS. The increased expression of
iNOS correlated with dopaminergic neuronal loss (Stefanova et al.,
2007; Fellner et al., 2013b). Furthermore, in this transgenic MSA
mouse model and in human MSA brains, an upregulation of TLR4 was
demonstrated, suggesting a possible attempt to increase phagocytotic
activity in these brains (Stefanova et al., 2007; Brudek et al., 2013). In
vivo experiments in a double transgenic mouse with a knock-out of
TLR4 and oligodendroglial overexpression of AS under the proteolipid
protein (PLP) promoter showed an impaired phagocytotic activity
similar to the in vitro experiments which presented with increased
motor disability and enhanced loss of nigrostriatal dopaminergic neu-
rons in the mouse. In addition, increased brain levels of AS were linked
to disturbed TLR4-mediatedmicroglial phagocytosis of AS. Conclusively,
TLR4 upregulation in microglial cells is suggested as a natural mecha-
nism to promote the clearance of extracellular AS in MSA (Stefanova
et al., 2011). In a very recent study, myeloperoxidase (MPO), a key
enzyme important for the production of ROS by phagocytotic cells,
was found to be upregulated in microglia of MSA post-mortem brains,
as well as in a MSA mouse model (Stefanova et al., 2012a). Inhibition
of this enzyme in the MSA mouse model revealed a rescue of neurons,
a reduced amount of intracellular AS and suppressed microgliosis
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of microglial cells as well as in the aggregation process of AS in MSA
(Stefanova et al., 2012a). Microglial cells play an important role in the
initiation and progression of MSA regarding phagocytosis, oxidative
stress and inﬂammation. However, the complete mechanisms inducing
AS-dependent microglial activation have not been elucidated to this
date. The role of microglial activation might be equally relevant in
MSA if compared to PD and DLB. Also in the context of MSA researchers
have to resolve the complete involvement of microglia in the disease
initiation and progression. Elucidation of the beneﬁcial and detrimental
functions of microglial activation on neuronal survival in ASP will
remain a major challenge for research.Astroglia
Astroglial activation is present in all ASP including MSA, and
seems to play a role in disease initiation and progression respectively.
In a Japanese study on the prognosis and progression of MSA,
astrogliosis was demonstrated in the striatonigral, olivopontocerebellar
and autonomic system, as well as in the corticospinal tract in MSA
post-mortem brains (Watanabe et al., 2002). Furthermore, extensive
astrogliosis has been conﬁrmed in MSA brains (Ozawa et al., 2004;
Jellinger et al., 2005) and moreover, AS-positive astroglial inclusions
have been described in MSA brains, however in a decreased density
compared to GCIs (Wenning and Jellinger, 2005). On the other hand
Song et al. rejected the assumption that astroglial AS accumulation
occurs in MSA cases (Song et al., 2009).Table 1
MSA invivomodelswith ASpathology. In this tablewe summarize all in vivomodels thatwere g
α-synuclein (AS) in oligodendroglial cells and neuronal loss. The replication of AS-positive a
Furthermore, different stressors [e.g. 3-nitropropionic acid (3-NP), inducingmitochondrial dysfu
inclusions, microglial and astroglial activation as well as neuronal loss. For a more detailed desc
(2013b), and Kuzdas-Wood et al. (2014)). This table is illustrative, but by no means complete.


















Myelin basic protein promoter
MBP-AS MSA
mouse model
Myelin basic protein promoter Mitochondrial inhibition by
systemic 3-NP administrationDifferent experimental data suggested that AS might be endocytosed
by astroglial cells and furthermore, AS might induce astroglial activa-
tion, including the release of pro-inﬂammatory cytokines and increased
oxidative stress (Lee et al., 2010; Fellner et al., 2013a). The summarized
in vitro studies for PD and DLB on AS-dependent astroglial activation
might be equally relevant for MSA (Fig. 2). Moreover, in different MSA
mouse models a role for astrogliosis in MSA-like neurodegeneration
has been indicated. Astrogliosis in various brain areas aswell as changes
in cytokine and chemokine expression levels were detected in a
MSA mouse model overexpressing AS in oligodendroglial cells under
the myelin basic protein promoter (Shults et al., 2005; Valera et al.,
2014). Moreover, astrogliosis has been also described in another MSA
mouse model overexpressing AS under the 2′,3′-cyclic nucleotide 3′-
phosphodiesterase (CNP) promoter (Yazawa et al., 2005). Furthermore,
astroglial activation accompanying neurodegeneration was reported in
a differentMSAmousemodel overexpressing AS under the PLP promot-
er exposed to 3-nitropropionic acid (3-NP) (Stefanova et al., 2005a)
(Table 1).
Astroglial activation seems to be an important factor in the patho-
genesis of MSA. However, to this date there is still insufﬁcient data on
the speciﬁc facets of astroglial responses related to MSA strengthening
the necessity for further studies to understand astrogliosis in the patho-
genesis of MSA.
Oligodendroglia
Asmentioned above the hallmark of MSA are GCIs which are mainly
located in oligodendroglial cells characterized by their major componentenerated to imitate themain pathological hallmarks ofMSA, including the accumulation of
ccumulations in vivo was initiated by using various oligodendroglial speciﬁc promoters.
nction]were tested to induce a full-blownMSApathology, includingwide-spreadGCI-like
ription of in vivoMSAmodels see Stefanova et al. (2005b), Ubhi et al. (2011), Fellner et al.
Additional abbreviations: SNpc— substantia nigra pars compacta, SND— striatonigral de-
Outcome
Insoluble AS inclusions, hyperphosphorylation at Serine 129 (Kahle et al., 2002)
Moderate dopaminergic neuronal loss in SNpc (Stefanova et al., 2005a)
Microglial activation (Stefanova et al., 2005a)
Cardiovascular autonomic and bladder dysfunction (Stemberger et al., 2010;
Boudes et al., 2013; Kuzdas et al., 2013)
Progressive motor phenotype (Stefanova et al., 2005a)
Widespread AS inclusion pathology
SND and OPCA
Profound astrogliosis and microgliosis
Profound motor and behavioral deﬁcits (Stefanova et al., 2005a,2005b)
Increased ﬁbrillized AS in oligodendroglia
Accelerated SND and OPCA
Myelin disruption and demyelination
Axonal degeneration
Motor impairment
(Stefanova et al., 2012b)
Accumulation of endogenous mouse AS in axons and axon terminals predominantly




Neuronal and oligodendroglial loss in the spinal cord
Motor impairment
(Yazawa et al., 2005)
Widespread insoluble AS inclusions, phosphorylation of AS at Serine 129
Loss of dopaminergic terminals in striatum
Astrogliosis
Reduced levels of several neurotrophic factors
Impaired motor phenotype
(Shults et al., 2005; Ubhi et al., 2010)
Augmented neurodegeneration
Altered levels of oxidized and nitrated AS
(Ubhi et al., 2009)
269D. Brück et al. / Neurobiology of Disease 85 (2016) 262–274namely AS (Papp et al., 1989; Kato and Nakamura, 1990; Kato et al.,
1991; Papp and Lantos, 1992; Arima et al., 1998; Spillantini et al.,
1998; Tu et al., 1998; Wakabayashi et al., 1998). The occurrence and
distribution of these GCIs in MSA led to the assumption that oligoden-
droglial cells must play a leading role in the initiation and progression
of MSA (Wenning and Quinn, 1994; Ozawa et al., 2001; Wenning et al.,
2008). In a postmortem study a correlation of GCI occurrence and neu-
rodegeneration was reported suggesting the important role of oligo-
dendroglial dysfunction in MSA progression (Ozawa et al., 2004).
GCIs have an extensive distribution throughout the CNS including
areas such as pons, medulla, putamen, SN, cerebellum and pregangli-
onic autonomic brain structures (Papp and Lantos, 1994; Nishie et al.,
2004; Beyer and Ariza, 2007; Jellinger and Lantos, 2010).
It is still an ongoing debate whether oligodendroglial cells do active-
ly incorporate and accumulate AS released by neurons or an elevated
expression and slow degradation of AS in oligodendroglial cells occur
and lead to GCI formation in MSA (Fellner et al., 2011; Ubhi et al.,
2011). Different studies demonstrated the active release of AS by
neurons into the extracellular space (Emmanouilidou et al., 2010;
Hansen et al., 2011). In a very recent study it was shown that grafted
OLN-93 rat oligodendroglial cells can incorporate extracellular injected
AS and AS fromhost rat brain neurons overexpressing human AS in vivo
(Reyes et al., 2014) strengthening the assumption of cell-to-cell propa-
gation mechanisms in MSA. A concentration-, time-, dynamin GTPase-,
clathrin- and dynasore-dependent uptake mechanism of different
forms of AS in oligodendroglial cells has been described in vitro (Kisos
et al., 2012; Konno et al., 2012; Reyes et al., 2014). Furthermore, a role
for oxidative stress regarding the uptake, accumulation and oligomeri-
zation of AS by OLN-93 oligodendroglial cells was demonstrated
(Pukass and Richter-Landsberg, 2014) (Table 2).
Moreover, Nakamura and colleagues found an ectopic expression of
Rab5 and Rabaptin-5 in GCIs of human oligodendrocytes. The enhanced
expression of Rab5 may trigger endocytosis and lead to abnormal
endocytotic activity resulting in the incorporation of elevated levels of
AS into oligodendroglial cells (Nakamura et al., 2000). These recent
data indicate that AS can be incorporated by oligodendroglial cells
from the extracellular space or neurons.
Different studies have shown lack of SNCAmRNA in oligodendroglial
cells of control and MSA brains (Ozawa et al., 2001; Miller et al., 2005).
In a very recent study Asi and colleagues isolated oligodendroglia by
laser-capture microdissection from MSA and control cases to perform
cellular expression analysis and suggested that oligodendroglial SNCATable 2
MSA in vitromodels. As themechanisms of glial cytoplasmic inclusions (GCI) formation have no
this neurodegenerative disease in vitro. This table is illustrative, but by no means complete, of
Cell type Ty
Overexpression in vitro models
U373 (Stefanova et al., 2001, 2003) Human astrocytoma cell line W
truPrimary rat oligos (Stefanova et al., 2001, 2003) Primary rat oligodendroglia
CG-4 (Tsuboi et al., 2005) Rat oligodendroglial progenitor cells W
OLN-t40-AS (Kragh et al., 2009, 2013) Rat oligodendroglial cell line W
Primary mouse oligos (Kragh et al., 2009, 2013) Primary mouse oligodendroglia
OLN-93 (Pukass and Richter-Landsberg, 2014) Rat oligodendroglial cell line W
Primary rat oligos (Pukass and
Richter-Landsberg, 2014)
Primary rat oligodendroglia
Uptake in vitro models
KG1C, MO3.13 (Konno et al., 2012) Human oligodendroglial cell lines M
M
Oli-neu, OLN-93 (Kisos et al., 2012) Rat oligodendroglial cell line W
Primary rat oligos (Kisos et al., 2012) Primary rat oligodendroglia
OLN-93 (Reyes et al., 2014) Rat oligodendroglial cell line W
olimRNA expression had a tendency of elevation in MSA oligodendroglia
however without reaching statistical signiﬁcance as compared to
healthy controls. Furthermore, no signiﬁcant differences were found
regarding the SNCA mRNA expression between MSA and control cases
in tissue extracts of various brain regions (Asi et al., 2014).
It is suggested that oligodendroglial cells are primarily injured
in MSA (Wenning et al., 2008) which might offer an explanation for
the pathological accumulation of AS in these cells. One mechanism
could be a defective degradation of AS in oligodendroglia in MSA in-
ducing an enhanced accumulation in these cells (Ebrahimi-Fakhari
et al., 2011; Schwarz et al., 2012; Stefanova et al., 2012b). A role for
macroautophagy regarding the degradation of AS in human oligoden-
droglial cells was proposed given that the inhibition of the proteasomal
system led to an increase of autophagy markers in cultured oligoden-
droglial cells. However, elevated levels of autophagy markers did not
enhance the degradation of AS. Moreover, the autophagy protein LC3
was found in GCIs suggesting a major role for macroautophagy in MSA
(Schwarz et al., 2012). Recently, it was suggested that the ubiquitin–
proteasome system might contribute to the aggregation of AS in MSA
(Stefanova et al., 2012b). Inhibition of the ubiquitin–proteasome system
revealed enhanced aggregation of ﬁbrillized AS in the cytoplasm of
oligodendroglia inducing myelin disruption and demyelination in a
MSA mouse model (Stefanova et al., 2012b). The histone deacetylase 6
(HDAC6) plays an important role in the regulation of the formation of
aggresomes (Kawaguchi et al., 2003) and aggresome degradation
(Iwata et al., 2005) regarding the transport of ubiquitinated misfolded
proteins, as well as the control of autophagy pathways (Pan et al.,
2008). The cytoplasmic enzyme HDAC6 was identiﬁed by Miki and col-
leagues in 98% of GCIs in post-mortem MSA brains (Miki et al., 2011).
This indicates that HDAC6 may promote the formation of ﬁbrillized AS
inclusions in oligodendroglial cells and suggests an important role for
HDAC6 inMSA progression. Furthermore, AS seems to be amajor factor
in the initiation of the formation of protein inclusions, as in the absence
of AS no accumulation of tau andαB-crystallin, further GCI components,
occurs (Riedel et al., 2009), indicating that AS acts as amajor initiator of
GCI formation.
Additionally p25α, an oligodendroglial phosphoprotein (tubulin po-
lymerization promoting protein)was shown to promote AS aggregation
in vitro (Lindersson et al., 2005). Song and colleagues found that p25α is
able to relocate to oligodendroglial soma in MSA cases, leading to an
early oligodendroglial dysfunction and causing MSA initiation and GCI
formation (Song et al., 2007). Furthermore, it was demonstrated thatt been elucidated to date, efforts aremade to identify probable pathways in the initiation of
the various in vitro experiments trying to ﬁgure out the pathogenesis of MSA.
pe of AS Outcome
ild type C-terminally
ncated
Increased susceptibility to oxidative stress
Induction of apoptotic cell death
TNF-α induced cell death
ild type Increased cell death
Impaired adhesion to ﬁbronectin
ild type Cytotoxicity: co-expression of AS and p25α relies on death
domain receptor FAS and caspase 8 activation
Co-expression leads to the disorganization of micro-tubular
cytoskeleton




Inhibition of dynamin GTPase lead to reduced AS uptake
ild type mutant A53T Uptake of neuron-derived or exogenously given AS
Clathrin-dependent uptake of AS
ild type (monomeric,
gomeric, ﬁbrillized)
Dynamin/dynasore-mediated uptake of exogenously given AS
Rare internalization of ﬁbrillized AS
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to disorganization of themicrotubular cytoskeleton and the stimulation
of the death domain receptor FAS as well as the activation of caspase-8
(Kragh et al., 2009, 2013). In addition,more recently an up-regulation of
FAS receptor in MSA brains was found, indicating that oligodendroglial
FAS ligand-mediated apoptosis might play an important role in MSA
(Kragh et al., 2013). The inhibition of the phosphorylation of Ser129 of
AS decreased the disorganization of the cytoskeleton and apoptosis
suggesting that AS phosphorylation might be a key mechanism in the
formation of AS oligomers and oligodendroglial cell death (Kragh
et al., 2009).
Oligodendroglial cells featuring GCI pathology in vitrowere found to
have changed properties and they seem to be more vulnerable to
different stimuli such as oxidative stress. In cell culture experiments,
glial cells overexpressing AS were more susceptible to oxidative stress
and TNF-α indicating that the higher oligodendroglial vulnerability to
cytokines and stress plays an important role in MSA pathogenesis
respectively (Stefanova et al., 2001, 2003). Moreover, a disturbed
cell–extracellular matrix interaction was demonstrated by Tsuboi and
colleagues who found that the overexpression of AS decreased the
adhesion to ﬁbronectin in CG-4 rat oligodendroglial cells (Tsuboi et al.,
2005) (Table 2). In animal models the oligodendroglial overexpression
of AS resulted in neuronal cell death in various regions of the brain
such as SNpc, locus coeruleus, nucleus ambiguous, pedunculopontine
tegmental nucleus, laterodorsal tegmental nucleus and Onuf's nucleus
(Stefanova et al., 2005a; Stemberger et al., 2010; Kuzdas et al., 2013).
Furthermore, increased myelin disruption and mitochondrial dysfunc-
tion were found in the MSA mouse models overexpressing AS under
an oligodendroglial promoter (Shults et al., 2005; Yazawa et al., 2005;
Stefanova et al., 2007). Oligodendroglial AS overexpression but not neu-
ronal AS overexpression led to a signiﬁcant decrease of glial cell-derived
neurotrophic factor (GDNF) as was also found in brain samples of MSA
patients (Ubhi et al., 2010) (Table 1).
These ﬁndings indicate that aggregation of AS in oligodendroglia
may lead to alterations of neurotrophic factors, oxidative stress and
neuroinﬂammation, which all together promote MSA pathogenesis.
In summary, oligodendroglial cells play a crucial role in the patho-
genesis of MSA including their vulnerability to different stress re-
sponses, the loss of trophic support and demyelination that further
lead to neurodegeneration. Moreover, the formation of AS inclusions
in these cells seems to be a keymechanism in disease initiation and pro-
gression. Unfortunately, the precise molecular and cellular mechanisms
underlying GCI formation and altered oligodendroglial function still
need to be unraveled. Additionally, detailed investigations using cell
culture and transgenic MSA models will greatly enhance the under-
standing of the MSA pathogenesis and might lead to the development
of new therapeutic targets.
Conclusion
Glial cells play an important role in the initiation and progression of
ASP due to their multifaceted responses to AS aggregation in various
brain areas. Especially microglial and astroglial cells respond to various
brain insults and get activated which includes the release of pro-
inﬂammatory cytokines or chemokines, ROS and NO. This stress re-
sponse can lead to neuronal dysfunction and degeneration due to the
chronic microgliosis and astrogliosis in brains of ASP patients. Further-
more, oligodendroglial cells develop AS-positive inclusions in MSA
inducing oligodendroglial dysfunction including demyelination and
reduced trophic support. All these detrimental features of glial cells
affect neuronal viability and survival. However, glial cells also display
beneﬁcial functions, i.e. phagocytosis of debris and AS by microglial
cells and the release of neurotrophic factors upon dopaminergic cell
death by astroglial cells. Therefore, it is impossible to categorize the
role of glial cells in the initiation and progression of ASP. To understand
the full contribution of glial cells to the pathogenesis of ASP furtherstudies are needed. To clarify the development of the inclusion bodies
in glial cells and neurons should be a main focus for researchers regard-
ing ASP. If we understand the mechanisms of the accumulation and
aggregation of AS and the impact of these inclusions on the progression
of these diseases, interventions with new therapeutic targets would be
possible. Furthermore, the understanding of these basic mechanisms
might also enable us to develop new biomarkers that help clinicians to
overcome limitations of early diagnoses of ASP. Moreover, an early
diagnosis would increase the chance to halt disease progression
maybe evenwith now available therapeutics that contain inﬂammation.
However, in vitro and in vivo experiments feature different limitations
that have to be taken into account. Generated in vitro data in mouse
or rat cells have to be conﬁrmed in human tissue and have to be trans-
ferred successfully into an in vivo system. Moreover, animal models,
especially rodent models, replicate rarely all aspects of the human dis-
eases and therefore gained results have to be carefully considered and
conclusions regarding the human disease have to be drawn cautiously.
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